Deans' stroke musings: Novel plasma panel advances noninvasive detection of Alzheimer’s disease

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, March 4, 2026

Novel plasma panel advances noninvasive detection of Alzheimer’s disease

Because of your extra risk of dementia, you need this so your competent? doctor CAN DELIVER THOSE EXACT ALZHEIMER PREVENTION PROTOCOLS!

With your risk of dementia, you need this.

1. A documented 33% dementia chance post-stroke from an Australian study? May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.`

3. A 20% chance in this research. July 2013.

4. Dementia Risk Doubled in Patients Following Stroke September 2018

But I bet your doctor has nothing! Good luck dealing with Alzheimer's on your own.

Novel plasma panel advances noninvasive detection of Alzheimer’s disease

In a study of 520 participants, researchers used mass spectrometry and machine learning to identify Alzheimer’s disease-specific structural changes in plasma proteins, developing a 3-marker panel that achieved 83% accuracy in distinguishing healthy individuals, mild cognitive impairment (MCI), and Alzheimer’s disease (AD), with area under the receiver operating characteristic curves (AUCs) exceeding 0.93 for key binary comparisons.

The findings, published in Nature Aging, suggest that plasma conformational biomarkers could offer a highly accurate, minimally invasive tool for early detection and disease monitoring, with important implications for clinical trial design and therapeutic intervention in AD.

“With this work, we established a potential new biomarker panel that reveals structural disruptions in proteins linked to Alzheimer’s disease that are invisible to traditional approaches,” said lead author John Yates, The Scripps Research Institute, La Jolla, California. “This approach accurately distinguishes stages of the disease, meaning that it could help enable earlier diagnosis.”

For the cross-sectional and longitudinal analysis, the researchers profiled plasma protein structural alterations in 520 participants using high-resolution mass spectrometry combined with machine learning algorithms. Participants included people with and without AD and MCI.

The investigators examined conformational changes linked to ApoE variants and neuropsychiatric symptoms, ultimately identifying a 3-peptide diagnostic panel derived from C1QA, CLUS, and ApoB that captured AD-specific structural signatures.

The resulting multi-marker panel achieved 83.44% accuracy in 3-way classification among healthy, MCI, and AD groups, with AUCs of 0.9343 for healthy versus MCI and 0.9325 for MCI versus AD.

Longitudinal samples were classified with 86% accuracy.

“This work introduces a fundamentally new, blood-based approach to detecting and staging Alzheimer’s disease,” commented Richard Hodes, National Institute on Aging, part of the National Institutes of Health, Bethesda, Maryland. “By revealing protein structural changes associated with genetic risk, symptom severity, and sex differences -- features not captured by existing biomarkers -- this research could enable earlier diagnosis and more effective clinical trials.”

Reference: https://www.nature.com/articles/s43587-026-01078-2

SOURCE: National Institutes of Health